Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures (2016 - 2022)

Arcus Biosciences has reported Gains from Sales and Divestitures over the past 7 years, most recently at $500000.0 for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures rose 30.83% year-over-year to $500000.0; the TTM value through Dec 2022 reached $500000.0, up 30.83%, while the annual FY2022 figure was $500000.0, 30.83% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $500000.0 at Arcus Biosciences, up from $382183.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $500000.0 in Q4 2022 and troughed at $6250.0 in Q4 2020.
  • A 5-year average of $255225.0 and a median of $372774.0 in 2019 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 98.32% in 2020 and later soared 6014.93% in 2021.
  • Year by year, Gains from Sales and Divestitures stood at $14918.0 in 2018, then skyrocketed by 2398.82% to $372774.0 in 2019, then plummeted by 98.32% to $6250.0 in 2020, then soared by 6014.93% to $382183.0 in 2021, then surged by 30.83% to $500000.0 in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for RCUS at $500000.0 in Q4 2022, $382183.0 in Q4 2021, and $6250.0 in Q4 2020.